Cytokine concentration
Mepolizumab treatment increased type-2 biomarker levels in sinonasal tissue at Week 24 vs baseline for IL-4 (4.48±3.77 vs 9.38±7.56,p =0.004), IL-5 (10.84±18.65 vs 63.98±50.66, p =0.001), IL-13 (4.02±2.57 vs 6.46±3.99, p =0.024) and GM-CSF (1.51±1.74 vs 4.50±2.97, p =0.001), as well as increased the regulatory cytokine IL-10 (5.07±3.98 vs 9.74±6.00, p =0.006) (Figure 3). There was no change in type-1 pro-inflammatory cytokines IL-1β (6.94±19.66 vs 1.41±1.24, p =0.264) and TNF-α (4.92 ± 7.08 vs 5.78 ± 2.98,p =0.625).